Skip to content
Home/Companies/Biotech/Versantis

Versantis

Biotech·Switzerland·Exited 2022·Held 5yr
Entry
2017
Hold
5yr
Exit
2022

Who owns Versantis?

Versantis was owned by Invivo Partners through Invivo Ventures (2019 vintage) from 2017 to 2022, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-09

Invivo Partners
Investor
Invivo Partners
Invivo Ventures · 2019 · Life Sciences VC

Key facts

HQSwitzerland
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2022

More from Invivo Ventures

Other portfolio companies in the same fund.

EsoBiotec
Exited 2025
BiotechBelgium· 2023
to
OneChain Immunotherapeutics
OneChain Immunotherapeutics
Active
BiotechSpain· 2023
Corteria Pharmaceuticals
Corteria Pharmaceuticals
Active
BiotechFrance· 2021
Integra Therapeutics
Integra Therapeutics
Active
BiotechSpain· 2021
ARTHEx Biotech
ARTHEx Biotech
Active
BiotechSpain· 2020
Gyala Therapeutics
Gyala Therapeutics
Active
BiotechSpain· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Versantis

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Versantis.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue